002550.SZ
Changzhou Qianhong Biopharma Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 6.50
−3.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.5B | 1.6B | 1.5B | 1.8B | 2.3B |
| Cost of Revenue | 588.1M | 654.3M | 689.1M | 1.0B | 1.4B |
| Gross Profit | 890.4M | 916.9M | 837.2M | 784.9M | 889.0M |
| Operating Expenses | |||||
| R&D Expense | 114.8M | 110.7M | 104.4M | 97.1M | 88.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 157.8M | 150.6M | 123.2M | 131.8M | 123.7M |
| Selling & Marketing Expense | 302.3M | 317.8M | 304.5M | 393.9M | 421.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 611.0M | 605.9M | 543.7M | 636.7M | 576.6M |
| Cost and Expenses | 1.2B | 1.3B | 1.2B | 1.7B | 2.0B |
| Operating Income (EBIT) | 371.3M | 455.6M | 396.4M | 204.4M | 360.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 365.9M | 450.2M | 395.8M | 203.5M | 360.3M |
| Income Tax Expense | 65.8M | 76.9M | 62.7M | 24.9M | 40.4M |
| Bottom Line | |||||
| Net Income | 322.9M | 398.8M | 356.0M | 181.9M | 323.4M |
| Earnings from Cont. Ops | 300.1M | 373.3M | 333.2M | 178.7M | 319.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 322.9M | 398.8M | 356.0M | 181.9M | 323.4M |
| Per Share | |||||
| Basic EPS | CN¥0.26 | CN¥0.32 | CN¥0.28 | CN¥0.14 | CN¥0.25 |
| Diluted EPS | CN¥0.26 | CN¥0.32 | CN¥0.28 | CN¥0.14 | CN¥0.25 |
| Revenue Per Share | CN¥1.18 | CN¥1.26 | CN¥1.20 | CN¥1.40 | CN¥1.78 |
| Shares | |||||
| Basic Shares Outstanding | 1.3B | 1.2B | 1.3B | 1.3B | 1.3B |
| Diluted Shares Outstanding | 1.3B | 1.2B | 1.3B | 1.3B | 1.3B |
| Profitability Metrics | |||||
| EBITDA | — | 525.2M | 466.3M | 277.3M | 428.3M |
| D&A | — | 69.6M | 69.9M | 73.0M | 68.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026